** Shares in ALK-Abello ALKb.CO jump around 16% after the
Danish pharmaceutical company's Q3 earnings beat expectations
thanks to sales growth, gross margin improvement, and a modest
decline in capacity costs
** Q3 EBIT jumped 128% in local currencies to DKK 147
million ($21.43 million), total revenue was up by 8% to DKK
1,110 million
** ALK-Abello maintained its FY outlook
** Sydbank says the company's turnover met the market's
expectations, while Q3 EBIT beat the expected DKK 104 million
** If gains hold, the stock will see its best day since 2009
($1 = 6.8585 Danish crowns)
(Reporting by Marta Frąckowiak)
((marta.frackowiak@thomsonreuters.com))